A recent study developed by the WifOR Institute and commissioned by IFPMA highlights the economic impact of the global pharmaceutical industry. The study demonstrates the valuable contribution that our industry brings to the global economy, in terms of GDP contribution, employment, and supply chain. Read more ⤵️ https://lnkd.in/dyZTgH8t
IFPMA’s Post
More Relevant Posts
-
🚨 Are you ready to take your business global? 🚨 Join us for this unique free #webinar "Opportunities for Expanding into International Markets for the #MexicanIndustry" and discover how Mexican pharmaceutical and chemical companies can leverage their competitive advantages to succeed in #InternationalMarkets. 🔗 Register here: https://lnkd.in/dNU9VfMF We'll be covering global trends, regulatory requirements, and strategies for overcoming trade barriers to help you identify new growth opportunities and strengthen your presence in key markets abroad. Speaker: Virgilio Garcia, LATAM West General Manager at SCIEX, Mexico – a seasoned leader with extensive experience in the pharmaceutical sector across Latin America. This session will set the stage for discussions at #TechPharmaNet - Mexico 2024. Don't miss this chance to expand your business horizon! 📅 Date: September 19, 2024 #PharmaceuticalIndustry #ExportOpportunities #InternationalBusiness #GlobalMarkets #TradeStrategies #Mexico2024 #PharmaInnovation #BusinessGrowth #RegulatoryCompliance
-
-
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/3VuYt7U
-
-
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/4g30kZR
-
-
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/4faqFUt
-
-
Manager, Ethics & Compliance | U.S Privacy and Confidentiality Office at KPMG | U.S. Navy Veteran
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/4glDrAg
-
-
#Goa is a key exporter of pharmaceutical products, and over 90% of the formulations manufactured are exported, contributing substantially to the state's GDP. Know more at: http://bit.ly/goa_02 #StateFocus #InvestInGoa #InvestIndia #InvestInIndia #Pharma #MakeInIndia NITI Aayog Department for Promotion of Industry and Internal Trade Ministry of Commerce and Industry, Government of India
-
-
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/4f5vPRr
-
-
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/3VviCud
-
-
#Goa is a key exporter of pharmaceutical products, and over 90% of the formulations manufactured are exported, contributing substantially to the state's GDP. Know more at: http://bit.ly/goa_02 #StateFocus #InvestInGoa #InvestIndia #InvestInIndia #Pharma #MakeInIndia NITI Aayog Department for Promotion of Industry and Internal Trade Ministry of Commerce and Industry, Government of India
-
-
Senior Executive | Digital Supply Chain Transformation | Customer Experience & Design Thinking | Music Enthusiast
U.S. pharma manufacturers have been wary of the generic drug market for decades. High costs, low margins and rising competition from foreign producers have transformed America’s generic landscape into a shrinking desert. Mary Rollman of KPMG LLP discusses the future of the supply chain for generics might in this PharmaVoice article. Read more https://bit.ly/49xpWvt
-
